Risk of skin ulcerations associated with oral nicorandil therapy: A population-based study

British Journal of Dermatology

Volumn 173, Issue 2, 2015, Pages 498-509

  Lee, M T G ^a   Lin, H Y ^b,c   Lee, S H ^a,d,e   Chang, S S ^f,g   Chen, S C ^a   Lee, C C ^a,h  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c Hsin Yi Lin Dermatological Clinic   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

NICORANDIL; VASODILATOR AGENT;

AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; ICD-9; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SKIN ULCER; ANGINA PECTORIS; CHEMICALLY INDUCED; ORAL DRUG ADMINISTRATION; RISK FACTOR;

ADMINISTRATION, ORAL; AGED; ANGINA PECTORIS; FEMALE; HUMANS; MALE; NICORANDIL; PROSPECTIVE STUDIES; RISK FACTORS; SKIN ULCER; VASODILATOR AGENTS;

EID: 84941170275     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13884     Document Type: Article

References (46)

1. Smith VM, Lyon CC,. Nicorandil: do the dermatological and gastrointestinal risks outweigh the benefits? Br J Dermatol 2012; 167: 1048-52.
2. Nakae I, Matsumoto T, Horie H, et al,. Effects of intravenous nicorandil on coronary circulation in humans: plasma concentration and action mechanism. J Cardiovasc Pharmacol 2000; 35: 919-25.
3. Taira N,. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview. J Cardiovasc Pharmacol 1987; 10 (Suppl. 8): S1-9.
4. Horinaka S,. Use of nicorandil in cardiovascular disease and its optimization. Drugs 2011; 71: 1105-19.
5. Hughes LO, Rose EL, Lahiri A, et al,. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol 1990; 66: 679-82.
6. Di Somma S, Liguori V, Petitto M, et al,. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993; 7: 119-23.
7. Meeter K, Kelder JC, Tijssen JG, et al,. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992; 20 (Suppl. 3): S59-66.
8. Lai C, Onnis E, Solinas R, et al,. [A new anti-ischemic drug for the treatment of stable effort angina pectoris: nicorandil. Comparison with placebo and isosorbide-5-mononitrate]. Cardiologia 1991; 36: 703-11 (in Italian).
9. Zhu WL, Shan YD, Guo JX, et al,. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J 2007; 71: 826-33.
10. Doring G,. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992; 20 (Suppl. 3): S74-81.
11. Sasaki J, Saeki Y, Kawasaki K, et al,. A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in patients with ischemic heart disease. Cardiovasc Drugs Ther 1992; 6: 471-4.
12. Guermonprez JL, Blin P, Peterlongo F,. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993; 14 (Suppl. B): 30-4.
13. Ulvenstam G, Diderholm E, Frithz G, et al,. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992; 20 (Suppl. 3): S67-73.
14. Swan Study Group. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999; 2: 213-17.
15. Boulinguez S, Bedane C, Bouyssou-Gauthier ML, et al,. [Giant buccal aphthosis caused by nicorandil]. Presse Med 1997; 26: 558 (in French).
16. Reichert S, Antunes A, Trechot P, et al,. Major aphthous stomatitis induced by nicorandil. Eur J Dermatol 1997; 7: 132-3.
17. Salim F, Joshi A, Hopkins C,. Ulceration of the nasal dorsum: a rare cause? J Laryngol Otol 2014; 128: 289-91.
18. Robinson A, Baker P, Stevenson H,. Nicorandil as a cause of perineal ulceration. Ulster Med J 2012; 81: 97.
19. Shams K, Mukkanna KS, Loney MD, et al,. Leg ulcers associated with nicorandil are possibly underdiagnosed. Clin Exp Dermatol 2013; 38: 193-4.
20. Mikeljevic J, Highet AS,. Nicorandil-induced leg ulceration without mucosal involvement. Clin Exp Dermatol 2011; 36: 372-3.
21. Yap T, Philippou P, Perry M, et al,. Nicorandil-induced penile ulcerations: a case series. BJU Int 2011; 107: 268-71.
22. van de Nieuwenhof HP, van der Vleuten CJ, de Hullu JA, et al,. Never forget medication as a cause: vaginal ulceration caused by nicorandil. Am J Obstet Gynecol 2009; 201: e5-6.
23. Chan SK, Harris MD, Baldwin PJ, et al,. Vulvovaginal ulceration during prolonged treatment with nicorandil. BJOG 2009; 116: 1403-5.
24. Fraser SJ, Pinion SB, Adamson B, et al,. Vulval ulceration induced by the potassium-channel activator Nicorandil: a case series of five patients. BJOG 2009; 116: 1400-2.
25. Bhatti I, Cohen SN, Bleiker T, et al,. Nicorandil-induced foreskin ulceration. Colorectal Dis 2009; 11: 424-5.
26. Lee BC, Allen PB, Caddy GR, et al,. Nicorandil associated colonic ulceration: case series of an increasingly recognized complication. Dig Dis Sci 2011; 56: 2404-8.
27. Malde S, Wilson A,. Rectal ulceration caused by the anti-anginal nicorandil: case report of a preventable complication. Patient Saf Surg 2010; 4: 10.
28. Abdelrazeq AS, Owen C, Smith L, et al,. Nicorandil-associated para-stomal ulceration: Case series. Eur J Gastroenterol Hepatol 2006; 18: 1293-5.
29. Toquero L, Briggs CD, Bassuini MM, et al,. Anal ulceration associated with Nicorandil: case series and review of the literature. Colorectal Dis 2006; 8: 717-20.
30. Egred M, Andron M, Morrison WL,. Nicorandil may be associated with gastrointestinal ulceration. BMJ 2006; 332: 889.
31. Campolmi N, Guy C, Cinotti E, et al,. Corneal perforation: another side effect of nicorandil. Cutan Ocul Toxicol 2014; 33: 96-8.
32. Fraunfelder FW, Fraunfelder FT,. Conjunctival and corneal ulceration associated with nicorandil. Cutan Ocul Toxicol 2014; 33: 120-1.
33. Trechot F, Batta B, Petitpain N, et al,. A case of nicorandil-induced unilateral corneal ulceration. Int Wound J 2014; 11: 238-9.
34. McKenna DJ, Donnelly J, Armstrong DK,. Nicorandil-induced leg ulceration. Br J Dermatol 2007; 156: 394-6.
35. Chang CH, Lin JW, Wu LC, et al,. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012; 55: 1462-72.
36. Chen YJ, Wu CY, Shen JL, et al,. Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan. J Am Acad Dermatol 2013; 69: 25-33.
37. Murray CJ, Vos T, Lozano R, et al,. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-223.
38. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
39. Bickers DR, Lim HW, Margolis D, et al,. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55: 490-500.
40. Lyder CH, Preston J, Grady JN, et al,. Quality of care for hospitalized Medicare patients at risk for pressure ulcers. Arch Intern Med 2001; 161: 1549-54.
41. Kumar RN, Gupchup GV, Dodd MA, et al,. Direct health care costs of 4 common skin ulcers in New Mexico Medicaid fee-for-service patients. Adv Skin Wound Care 2004; 17: 143-9.
42. Trechot P, Jouzeau JY, Brouillard C, et al,. Role of nicotinic acid and nicotinamide in nicorandil-induced ulcerations: from hypothesis to demonstration. Int Wound J 2013; doi: 10.1111/iwj.12147.
43. Medicines and Healthcare products Regulatory Agency. Nicorandil 10 mg and 20 mg tablets. Available at: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con126185.pdf (last accessed 30 April 2015).
44. Grey JE, Harding KG, Enoch S,. Venous and arterial leg ulcers. BMJ 2006; 332: 347-50.
45. Schnier BR, Sheps SG, Juergens JL,. Hypertensive ischemic ulcer. A review of 40 cases. Am J Cardiol 1966; 17: 560-5.
46. Yola M, Lucien A,. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731-7.